132 related articles for article (PubMed ID: 10892990)
1. Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746.
Restrepo MI; Najvar LK; Barchiesi F; Luther MF; Graybill JR
Med Mycol; 2000 Jun; 38(3):221-4. PubMed ID: 10892990
[TBL] [Abstract][Full Text] [Related]
2. In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and comparison with fluconazole.
Stevens DA; Aristizabal BH
Diagn Microbiol Infect Dis; 1997 Oct; 29(2):103-6. PubMed ID: 9368086
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.
Miller JL; Schell WA; Wills EA; Toffaletti DL; Boyce M; Benjamin DK; Bartroli J; Perfect JR
Antimicrob Agents Chemother; 2004 Feb; 48(2):384-7. PubMed ID: 14742184
[TBL] [Abstract][Full Text] [Related]
4. Comparison of D0870 and fluconazole in the treatment of murine cryptococcal meningitis.
Correa AL; Velez G; Albert M; Luther M; Rinaldi MG; Graybill JR
J Med Vet Mycol; 1995; 33(6):367-74. PubMed ID: 8683404
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
Perfect JR; Cox GM; Dodge RK; Schell WA
Antimicrob Agents Chemother; 1996 Aug; 40(8):1910-3. PubMed ID: 8843302
[TBL] [Abstract][Full Text] [Related]
6. Efficacies of two novel azole derivatives each containing a morpholine ring, UR-9746 and UR-9751, against systemic murine coccidioidomycosis.
Clemons KV; Stevens DA
Antimicrob Agents Chemother; 1997 Jan; 41(1):200-3. PubMed ID: 8980782
[TBL] [Abstract][Full Text] [Related]
7. Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.
Wiederhold NP; Kovanda L; Najvar LK; Bocanegra R; Olivo M; Kirkpatrick WR; Patterson TF
Antimicrob Agents Chemother; 2016 Sep; 60(9):5600-3. PubMed ID: 27324761
[TBL] [Abstract][Full Text] [Related]
8. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease.
Friese G; Discher T; Füssle R; Schmalreck A; Lohmeyer J
AIDS; 2001 Nov; 15(17):2344-5. PubMed ID: 11698718
[No Abstract] [Full Text] [Related]
9. Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis.
Ding JC; Bauer M; Diamond DM; Leal MA; Johnson D; Williams BK; Thomas AM; Najvar L; Graybill JR; Larsen RA
Antimicrob Agents Chemother; 1997 Jul; 41(7):1589-93. PubMed ID: 9210691
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.
Larsen RA; Bauer M; Thomas AM; Graybill JR
Antimicrob Agents Chemother; 2004 Mar; 48(3):985-91. PubMed ID: 14982793
[TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
[TBL] [Abstract][Full Text] [Related]
12. Fluconazole-resistant cryptococcal meningitis.
Momoff N; Parrish A
S Afr Med J; 2003 Jun; 93(6):444. PubMed ID: 12916384
[No Abstract] [Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.
Sudan A; Livermore J; Howard SJ; Al-Nakeeb Z; Sharp A; Goodwin J; Gregson L; Warn PA; Felton TW; Perfect JR; Harrison TS; Hope WW
Antimicrob Agents Chemother; 2013 Jun; 57(6):2793-800. PubMed ID: 23571544
[TBL] [Abstract][Full Text] [Related]
14. The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis.
Wiederhold NP; Najvar LK; Garvey EP; Brand SR; Xu X; Ottinger EA; Alimardanov A; Cradock J; Behnke M; Hoekstra WJ; Schotzinger RJ; Jaramillo R; Olivo M; Kirkpatrick WR; Patterson TF
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987152
[TBL] [Abstract][Full Text] [Related]
15. Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans.
Larsen RA; Bauer M; Thomas AM; Sanchez A; Citron D; Rathbun M; Harrison TS
Antimicrob Agents Chemother; 2005 Aug; 49(8):3297-301. PubMed ID: 16048939
[TBL] [Abstract][Full Text] [Related]
16. New guinea pig model of Cryptococcal meningitis.
Kirkpatrick WR; Najvar LK; Bocanegra R; Patterson TF; Graybill JR
Antimicrob Agents Chemother; 2007 Aug; 51(8):3011-3. PubMed ID: 17562797
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis.
Nguyen MH; Najvar LK; Yu CY; Graybill JR
Antimicrob Agents Chemother; 1997 May; 41(5):1120-3. PubMed ID: 9145879
[TBL] [Abstract][Full Text] [Related]
18. Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance.
Hope W; Stone NRH; Johnson A; McEntee L; Farrington N; Santoro-Castelazo A; Liu X; Lucaci A; Hughes M; Oliver JD; Giamberardino C; Mfinanga S; Harrison TS; Perfect JR; Bicanic T
mBio; 2019 Dec; 10(6):. PubMed ID: 31796539
[TBL] [Abstract][Full Text] [Related]
19. Cryptococcus neoformans var neoformans resistant to fluconazole in an HIV-negative patient with chronic lymphocytic leukemia.
Assing K; Birgens H; Arendrup M
Clin Microbiol Infect; 2003 May; 9(5):441-4. PubMed ID: 12848761
[TBL] [Abstract][Full Text] [Related]
20. Development of secondary resistance to fluconazole in Cryptococcus neoformans isolated from a patient with AIDS.
Alves SH; Lopes JO; Costa JM; Klock C
Rev Inst Med Trop Sao Paulo; 1997; 39(6):359-61. PubMed ID: 9674289
[No Abstract] [Full Text] [Related]
[Next] [New Search]
